2,461 Quest Diagnostics Incorporated $DGX Shares Acquired by Prime Capital Investment Advisors LLC

Prime Capital Investment Advisors LLC raised its position in Quest Diagnostics Incorporated (NYSE:DGX) by 257.7% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,416 shares of the medical research company’s stock after buying an additional 2,461 shares during the quarter. Prime Capital Investment Advisors LLC’s holdings in Quest Diagnostics were worth $796,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in DGX. BlackRock Inc. bought a new position in shares of Quest Diagnostics during the 2nd quarter worth $1,965,923,000. EdgePoint Investment Group Inc. raised its stake in Quest Diagnostics by 35.1% in the 1st quarter. EdgePoint Investment Group Inc. now owns 2,243,869 shares of the medical research company’s stock valued at $439,753,000 after acquiring an additional 582,797 shares during the period. Bank of America Corp DE bought a new stake in Quest Diagnostics in the 2nd quarter valued at about $410,151,000. Dimensional Fund Advisors LP raised its stake in Quest Diagnostics by 0.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,949,535 shares of the medical research company’s stock valued at $382,085,000 after acquiring an additional 17,987 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in Quest Diagnostics by 11.3% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 942,407 shares of the medical research company’s stock valued at $199,743,000 after purchasing an additional 95,804 shares during the last quarter. Hedge funds and other institutional investors own 88.06% of the company’s stock.

Insider Activity

In other news, SVP Mark Delaney sold 1,600 shares of the stock in a transaction dated Tuesday, July 28th. The shares were sold at an average price of $235.18, for a total value of $376,288.00. Following the sale, the senior vice president directly owned 10,335 shares of the company’s stock, valued at approximately $2,430,585.30. This represents a 13.41% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO J. Davis sold 10,000 shares of the stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $242.72, for a total transaction of $2,427,200.00. Following the completion of the sale, the chief executive officer directly owned 122,423 shares in the company, valued at approximately $29,714,510.56. The trade was a 7.55% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 34,277 shares of company stock worth $8,316,493 over the last ninety days. Company insiders own 0.88% of the company’s stock.

Quest Diagnostics Price Performance

Quest Diagnostics stock opened at $241.49 on Friday. Quest Diagnostics Incorporated has a one year low of $171.18 and a one year high of $248.84. The business has a fifty day moving average price of $237.67 and a 200-day moving average price of $216.82. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.70 and a quick ratio of 1.46. The firm has a market capitalization of $26.65 billion, a P/E ratio of 22.04, a PEG ratio of 2.19 and a beta of 0.54.

Quest Diagnostics (NYSE:DGX) last announced its quarterly earnings results on Thursday, October 22nd. The medical research company reported $3.00 earnings per share for the quarter, beating the consensus estimate of $2.87 by $0.13. Quest Diagnostics had a return on equity of 16.21% and a net margin of 9.53%. The company had revenue of $3.10 billion during the quarter, compared to analysts’ expectations of $3.05 billion. During the same period in the previous year, the business earned $2.60 earnings per share. The firm’s quarterly revenue was up 10.0% compared to the same quarter last year. As a group, equities research analysts forecast that Quest Diagnostics Incorporated will post 11.23 EPS for the current year.

Quest Diagnostics Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, October 21st. Stockholders of record on Tuesday, October 6th were given a dividend of $0.86 per share. The ex-dividend date was Tuesday, October 6th. This represents a $3.44 annualized dividend and a dividend yield of 1.4%. Quest Diagnostics’s dividend payout ratio is currently 36.52%.

Analysts Set New Price Targets

DGX has been the subject of a number of research reports. Weiss Ratings upgraded shares of Quest Diagnostics from a “buy (a)” rating to a “buy (a+)” rating in a research report on Wednesday. Robert W. Baird set a $262.00 target price on shares of Quest Diagnostics in a research note on Friday. UBS Group reissued a “neutral” rating and issued a $250.00 price target on shares of Quest Diagnostics in a research report on Monday. Jefferies Financial Group restated a “buy” rating and set a $245.00 price target on shares of Quest Diagnostics in a research note on Thursday, July 23rd. Finally, JPMorgan Chase & Co. upped their price target on shares of Quest Diagnostics from $220.00 to $250.00 and gave the company a “neutral” rating in a research note on Tuesday, July 28th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $244.27.

Trending Headlines about Quest Diagnostics

Here are the key news stories impacting Quest Diagnostics this week:

• Positive Sentiment: Third-quarter results beat estimates: Quest reported adjusted EPS of $3.00 versus the $2.87 consensus and revenue of $3.10 billion versus expectations of $3.05 billion. Revenue increased 10% year over year, while adjusted EPS rose 15.4%, reflecting stronger testing demand and margin improvement. Quest Diagnostics Reports Third Quarter 2026 Financial Results
• Positive Sentiment: Full-year guidance was raised: Quest now expects 2026 revenue of $12.065 billion to $12.105 billion and adjusted EPS of $11.25 to $11.35, above consensus estimates of approximately $12.0 billion and $11.19, respectively. Organic requisition volume rose 14.4% in the quarter, and consumer-health revenue is expected to grow more than 30% for the year. Quest Diagnostics Earnings Takeaways
• Positive Sentiment: Valuation and momentum remain supportive: Coverage characterized DGX as potentially undervalued following the guidance increase, while Zacks highlighted the company’s long-term momentum profile. Quest Diagnostics Could Be Undervalued
• Neutral Sentiment: Deutsche Bank raised its price target to $245 from $232 but maintained a Hold rating, indicating improved expectations without a clear bullish endorsement. Deutsche Bank Adjusts Quest Diagnostics Price Target
• Negative Sentiment: Patient-data breach creates a major overhang: Quest disclosed unauthorized access to its Quanum Lab Services Manager, a system used to order tests and access results. The company confirmed that personal and health information was compromised, potentially exposing it to regulatory scrutiny, litigation, remediation costs, and reputational damage. Quest Diagnostics Patient Data Breach

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated (NYSE: DGX) is a provider of diagnostic information services. The company performs laboratory testing that helps physicians, hospitals and other healthcare providers diagnose, treat and monitor diseases and health conditions. Its services include routine blood and other specimen testing, pathology, molecular and genetic testing, and specialized diagnostic services.

Quest Diagnostics serves a broad range of customers, including hospitals, physician practices, health plans, employers, government agencies and individual consumers.